| Literature DB >> 32256134 |
Masoud Ferdosi1, Reza Rezayatmand2, Yasamin Molavi Taleghani3.
Abstract
BACKGROUND: This study attempted to present a framework and appropriate techniques for implementing risk management (RM) in executive levels of healthcare organizations (HCOs) and grasping new future research opportunities in this field.Entities:
Keywords: executive levels; health care; organization risk management; risk analysis; scoping review
Year: 2020 PMID: 32256134 PMCID: PMC7090183 DOI: 10.2147/RMHP.S231712
Source DB: PubMed Journal: Risk Manag Healthc Policy ISSN: 1179-1594
Search Strings for Research Questions and Studies
| Code | Search Strings | Online Databases | Field | Quantity |
|---|---|---|---|---|
| RQ1 | (risk OR failure* OR error* OR event*) AND (source* OR classification* OR identify* OR category* OR epidemiology) AND (organization* OR system* OR administration*) NOT clinical* | PubMed | Title, Mesh, and Abstract | 164 |
| ISI | Title, Topic, and Abstract | 495 | ||
| Scopus | Title, Abstract, keywords | 284 | ||
| Emerald | Title, Abstract, keywords | 114 | ||
| ProQuest | Title, Abstract, keywords | 102 | ||
| Cochrane | Title, Abstract, keywords | 28 | ||
| Wiley | Title, Abstract, keywords | 49 | ||
| Springer | Title, Abstract, keywords | 30 | ||
| IEEE | Title, Mesh, and Abstract | 21 | ||
| RQ2 | (“risk management*” OR “risk assessment*” OR “management risk*” OR “assessment risk” OR “ risk analysis*”) AND (model* OR approach* OR technique* OR method* OR structure* OR tool* OR process* OR framework*) AND (organization* OR system* OR administration*) | PubMed | Title, Mesh and Abstract | 387 |
| ISI | Title, topic, and Abstract | 273 | ||
| Scopus | Title, Abstract, keywords | 838 | ||
| Emerald | Title, Abstract, keywords | 235 | ||
| ProQuest | Title, Abstract, keywords | 61 | ||
| Cochrane | Title, Abstract, keywords | 24 | ||
| Wiley | Title, Abstract, keywords | 215 | ||
| Springer | Title, Abstract, keywords | 63 | ||
| IEEE | Title, Abstract, keywords | 191 |
Paper Selection Process
| Phase | Number of Imported | Number of Excluded | Exclusion Criteria | |
|---|---|---|---|---|
| Identification | First iteration on data base | 3574 | – | R0: Disproportionate to the goals and research questions |
| Screening | Duplicate citations | – | 761 | |
| Title screening | 2813 | 1556 | ||
| Abstract screening | 1257 | 1081 | ||
| Eligibility | Full-text eligibility | 176 | 144 | |
| Included | Relevant papers found from the search on database | 32 | - | |
| Relevant references on references of relevant papers | 5 | - | ||
| Achieving the relevant papers | 37 | - |
Note: Each study may answer several research questions.
Bibliographical Sources of the Studies Included in the Literature Review
| 1 | Molavi Taleghani | 2016 | 4 | 1,2,3,4,5 | Iran | Emergency surgery ward in hospital | 2,3 |
| 2 | Gervais | 2012 | 3 | 2,4,5 | Ireland | Pharmaceutical manufacturing environment | 2,3 |
| 3 | Bernardini | 2013 | 3 | 2 | Italy | Complex and mission-critical systems | 2,3 |
| 4 | Cagliano | 2011 | 3 | 6 | Italy | Pharmacy department in a large hospital | 2,3,1 |
| 5 | Parand | 2017 | 4 | 1,4,5 | England+ Italy | Medication administration within homecare | 1,2,3 |
| 6 | Sendlhofer | 2015 | 3 | 2,6 | Austria | Large university hospital | 2,3 |
| 7 | Lopez | 2010 | 4 | 2,3 | USA | Clinical cell therapy in regenerative medicine | 2,3 |
| 8 | Emblemsvag | 2002 | 3 | 6,2 | Norway | Manufacturing environment | 1,2,3 |
| 9 | Jaberidoost | 2015 | 4 | 1,2,3,5 | Iran | Pharmaceutical industry | 2,3 |
| 10 | Wierenga | 2009 | 3 | 5,3 | Netherlands | Two hospital | 2,3 |
| 11 | Niel-Laine | 2011 | 2 | 2,5 | France | A central sterile supply department | 2,3,1 |
| 12 | Trucco | 2006 | 2 | 1,2,4,3 | Italy | Drug therapy management process | 2,3 |
| 13 | Emre Simsekler | 2018 | 4 | 1,2,6 | England | Gastroenterology Unit in Hospitals | 1,3 |
| 14 | Bonnabry | 2005 | 4 | 5 | Switzerland | Pediatric parenteral nutrition process | 2,3 |
| 15 | Rezaei | 2018 | 4 | 2,5,1,3 | IRAN | Surgery ward in hospital | 2,3 |
| 16 | Domanski | 2016 | 3 | 1,2,3 | Poland | Nonprofit Organizations | 1,2,3 |
| 17 | Ramkumar | 2016 | 4 | 2,5,6 | India | E-procurement systems | 1,2,3 |
| 18 | Beauchamp-Akatova | 2013 | 3 | 2,3,6 | Netherlands | Air transport systems | 2,3 |
| 19 | Faiella | 2017 | 4 | 2,3,6 | Uk | Administration of medication in the home setting | 2,3 |
| 20 | Usman Tariq | 2013 | 3 | 6,2 | Saudi Arabia | Iodine development industry | 1,2,3 |
| 21 | Famiyeh | 2015 | 4 | 3,1,5,4 | Ghana | Mining organization | 2,3 |
| 22 | Choo | 2015 | 4 | 6,1,3,4,5 | USA | Business unit within a large high-tech organization | 1,2,3 |
| 23 | Apostolopoulos | 2016 | 4 | 3,5,6 | UK | Various industries | 1,2,3 |
| 24 | Delcea | 2016 | 1 | 2,6 | Romania | Clinical Emergency County Hospital | 1,3 |
| 25 | Abdi | 2016 | 4 | 6,4,3,5 | Iran | Intensive care unit | 2,3 |
| 26 | Chu | 2014 | 4 | 5,6 | Taiwan | E-healthcare architecture and syndrome test | 2,3 |
| 27 | Prijatelj | 2012 | 3 | 5,3 | Slovenia | Selected clinical departments | 2,3 |
| 28 | Kerckhoffs | 2013 | 2 | 1,5 | Netherlands | Intensive Care Unit of in hospital | 2,3 |
| 29 | Vahidnia | 2017 | 2 | 1,3,6,2,4 | Turkey | Small software company in a University | 2,3 |
| 30 | Leung | 2008 | 3 | 1,2,3,5 | Canada | Public sector research | 2,3 |
| 31 | Zeng | 2013 | 3 | 2 | USA | Enterprise resource planning (ERP) systems | 2,3 |
| 32 | MC Emre Simsekl | 2015 | 4 | 1,2,4 | UK | University Hospitals Foundation Trust | 1,3 |
| 33 | M. C. Emre Simsekler | 2018 | 2 | 3,1 | UK | Health-care Foundation Trust | 3 |
| 34 | Jun | 2010 | 4 | 2,6,3,1 | UK | Health service | 3 |
| 35 | Card | 2014 | 1 | 5,1 | USA | Healthcare organization | 3 |
| 36 | Potts | 2014 | 4 | 1,5,3,2,4 | UK | Community-based anticoagulation clinic | 2,3 |
| 37 | Kessels-Habraken | 2009 | 4 | 1,2,4,5 | Netherlands | General hospital | 2,3 |
Notes: *Type of study included 1) Empirical quantitative; 2) Empirical qualitative 3) Conceptual/theoretical 4) mixed method. Data collection methods included 1) Survey (questionnaires or checklists); 2) Database, Documents & Records; 3) Interviews; 4) observation; 5) Focus Groups; 6) Ethnographies, Oral History, & Case Studies.
Identification and Classification of Risks in Executive Levels of Healthcare Organization
| Input | Process | Output |
|---|---|---|
| Customers and stakeholders demands (patients, providers, suppliers, and buyers) | All organizational processes (clinical and non-clinical processes, technology processes, etc.) | Customer perceptions, costs, functions and health status |
| Source of risk | Intra-organizational | Risk |
| 1- Internal: | A: Expert opinion(focus groups-brainstorming- Delphi technique) | Hazard: what can go wrong? |
| Extra-organizational | ||
| A: Literature | ||
| Retrospective | ||
| A: Expert opinion | ||
| Nature of hazards | Prospective | |
| A: Obvious hazard: Is apparent to the senses | A: Level of probability | |
| Time | ||
| A: Past: what has gone wrong the past? |
Characteristics of Organization RM and Risk Analysis Techniques
| Model Name | Steps | Characteristics | Output and Information | Attitude to the Risk | Applicable Type of Environment | Cost | Time | Complexity | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Establish the Context | Risk Identification | Risk Analysis | Risk Evaluation | Risk Treatment | Monitoring | |||||||||
| 1- Risk Analysis Phases | ||||||||||||||
| 1-1- Base models | ||||||||||||||
| Strategic risk analysis approach (SRA) | 1 - Define objectives, 2 -Brainstorm risk, and characteristics according to the SWOT axis; 3 - Calculate possibilities and consequence of the risks; 4 - Combine risks with characteristics. | Weakness: It does not express the relationship between risks and its nature. | N | S | Y | Y | N | N | *Qualitative | Particularly risks associated with the mission and objectives of the organization | Low-medium | Low-medium | Low-medium | |
| Preliminary Risk Analysis method (PRA) | 1. PRA team; 2. Elaborating hazardous situations mapping and priority; 3. Elaboration of potential risks scenario. | Strength: An effective tool for identifying high-risk dangers | Y | S | Y | Y | Y | Y | *Holistic | All, especially the early stages of a project | Low-medium | Low-medium | Low-medium | |
| Healthcare Failure Mode and Effect Analysis | 1. Selection of a high-risk process; 2. Assembling the team; 3. Graphically describing the processes; 4. Conducting hazard analysis; 5. Actions and outcome measures. | Weakness: 1. Use qualitative and subjective approaches to calculate error. | Y | Y | Y | Y | S | N | *Systemic | All, especially for | Medium | Medium | Medium | |
| Criticality analysis (FMECA) | 1. Team formation, 2. Process mapping, 3. Risk identification, 4. Determination of error roots, 5. Criticality, 6. Analysis, 7. Determine corrective actions. | Weakness: 1. Use qualitative and subjective approaches to calculate error. | Y | Y | Y | Y | S | N | *Systemic | All, especially for | Medium | Medium | Medium | |
| Change Risk Assessment Model (CRAMS) | 1. Risk Identification; 2. Risk Assessment; 3. Risk Monitoring & Control CRAM’s Node Hierarchy. | Weakness: Depend on the expert judgment. | Y | S | Y | Y | Y | Y | *Prospective | All, especially for the analysis of recent changes in systems | Low-medium | Low-medium | Low-medium | |
| Using a GRPN-Based FMEA Model | 1. Select a procedure/sub procedure for study; 2. Assemble a team; 3. Make a diagram of the procedure/subprocedure; 4. Identify the failure modes; 5. Use historical data of risk factors 6-Give α and risk weights; 6. Suggest threshold; 7. Create an FMEA worksheet; 8. Sort the failure modes; 9. Take corrective action. | Strength: Using quantitative parameters to estimate and prioritize errors | Y | S | Y | Y | Y | N | *Systemic | All, especially for | Medium | Medium | Medium | |
| Bow-Tie Model | 1. Selection of hazards; 2. Description of the team formation; 3. Identify hazard; 4-Identify critical event; 5. Identify treat; 6. Identify consequence ;7-Identify barrier; 8. Identify escalation factor; 9. Determining recommendation and implemented. | Weaknesses: | S | S | Y | Y | Y | N | *Prospective | All, especially for | medium | medium | medium | |
| 1-2 Combined Models | ||||||||||||||
| Analytic hierarchy process and simple additive weighting (SAW) methods | 1. Risk identification; 2. Risk analysis included 2-1. Scoring hazards; 2-2. Scoring probability; 2. 3Prioritize function; 2-4. Pilot study; 2–5. Risk analysis matrix; 3. Risk evaluation included 3-1. Risk calculation; 3-2. Risk ranking. | Strength: 1. Use of quantitative approaches to risk estimation | Y | S | Y | Y | N | N | *Qualitative-quantitative | All | Medium | Medium | Medium | |
| Evidence-based methodology | Be used by three methods: | Strength: | Y | Y | Y | Y | Y | Y | *Prospective | All, specially system accidents | Medium-high | High | High | |
| Human Reliability Assessment | 1. Context analysis; 2. Process mapping; 3. Risk identification and assessment; 4. Failure modes and waste analysis; 5. Suggested improvement actions and degree of success of already taken measures. | Strength: Combined model | Y | Y | Y | N | S | N | *Systemic-humanistic | All | Medium-high | Medium-high | Medium-high | |
| (FMEA/FMECA) | 1. Selection of the process to be studied; 2. Establishment of the team; 3. Training; 4. Process modeling flowchart; 5. Identification of potential failure mode; 6. Identification of possible consequences; 7. Identification of possible causes; 8. Estimation S, O, D; 9. Calculation of risk priority; 10. Decision; 11. Approval. | Strength: Combined model | S | Y | Y | Y | Y | N | *Systemic | All, especially for | Medium-high | Medium-high | Medium-high | |
| CREA (Clinical Risk and Error Analysis method) | 1. Activities Identification; 2. Activities; 3. Identification of error modes based HUMAN HAZOP; 4. Risk Evaluation based risk diagram; 5. Organizational Causes Analysis based VINCENT’S FRAMEWORK. | Strength: The decision support tool is for process reengineering | N | Y | Y | Y | N | N | *Holistic | All, especially Identify possible deviations and sequential operations or procedures | High | High | High | |
| Multiple models | Be used by three methods: | Strength: Combined model | Y | S | Y | Y | S | Y | *Narrow | All | High | High | High | |
| integrating FMEA and RCA | 1. Initial framework development; 2. Forming FDG group; 3. Selecting a process; 4. Mapping of selected process; 5. Implementation of the FMEA | Strength: Combined model | Y | S | Y | Y | S | Y | *Narrow | All, especially for | Medium-high | Medium-high | Medium-high | |
| Modified ANP and Fuzzy Inference System risk assessment | 1. Construction of risk assessment group; 2. Determine risk factors; 3. Measurement of Factor index; 4. Measurement of Ringer-saline (RS) or Ringer-lactate (RL); 5. Fuzzy inference phase; 6. Defused phase; 7. Output phase. | Strength: 1-Combined model | Y | S | Y | Y | S | N | *Retrospective- Prospective | All | Medium-high | Medium-high | Medium-high | |
| a fuzzy method based tool the risk assessment analysis | 1. Risk Factors, Scales and Data; 2. Identify Risk score; 3. Risk evaluation included 3-1. Risk matrix; 3-2. A decision matrix; 3-3. Obtained values as a vector of fuzzy numbers. | Strength: is suitable for small business organizations with limited resources. | S | Y | Y | Y | S | N | *Qualitative-quantitative | All, specially at project bid, initiation | Medium | Medium | Medium | |
| HFMEA and Structured What If Technique (SWIFT) | Be used by two methods: | Strength: 1-Combined model | Y | Y | Y | Y | Y | N | *Narrow | All, especially for | Medium | Medium | Medium | |
| Prospective risk analyses and | Prospective risk analyses: | Strength: 1. Combined model | Y | Y | Y | Y | S | N | *Narrow | All | Medium | Medium | Medium | |
| 2- Risk Management Phases | ||||||||||||||
| 2-1- Base models | ||||||||||||||
| Systemic Risk Management’ (SYRMA) | 1. defining and managing event and recording threats and vulnerabilities; 2. tracking identified risks in a risk register; 3. performing risk assessment and risk evaluation; 4. providing the capability of registering statistical or benchmark data; 5. setting risk priorities; 6. defining and tracking risk treatment activities. | Strength:1-address both managerial and operative staff support requirements.2-Allows users to personalize their view of the | S | Y | Y | Y | Y | Y | *Qualitative-quantitative | All, especially for healthcare sector and case of complex and mission critical systems | Medium-high | Medium-high | Medium-high | |
| Clinical risk management | 1. Identify risks; 2. Analysis risks; 3. Assess risks; 4. Manage risks. | Weakness: is based on subjective and intrinsic judgment | S | S | Y | N | S | Y | *Qualitative *Prospective | All, specially for healthcare | Medium-high | Medium-high | Medium-high | |
| Strategic Risk Management | 1. Defining the context; 2. Risk assessment; 3. Making and Communicating the decision and Action; 4. Monitoring and course correcting. | Weakness: is based on subjective and intrinsic judgment | Y | S | Y | Y | S | Y | *Qualitative *Prospective | All, specially for project management | Medium-high | Medium-high | Medium-high | |
| System risk evaluation and management | 1. Define the objectives and performance measures; 2. Workshop together; 3. Evaluate and priorities consequences for each alternative; 4. Evaluate system consequences and choose the best risk treatment; 5. Implement; 6. Monitor. | Strength: | Y | S | Y | Y | Y | Y | *Systemic | All, specially for dynamic and changing organization | Medium-high | Medium-high | Medium-high | |
| ISO 31000 | 1. Establish the context; 2. Identify risk; 3. Analysis risk; 4. Evaluate risks; 5. Treat risks; 6. Monitor and review; 7. Communication and consult. | Weakness: is based on subjective and intrinsic judgment | Y | Y | Y | Y | Y | Y | *Qualitative *Prospective | All | Medium-high | Medium-high | Medium-high | |
| ERM(enterprise risk management) | 1. Establish the context; 2. -Identify risks within this context; 3. Assess risks included: 3-1. analyze risks; 3-2. Evaluate risks; 4. Develop risk treatment included 4-1. Risk mitigation; 4-2. Implement mitigation strategies. | Weakness: The relative risk assessment matrix is used instead of a precise measurement for risk rating. | Y | Y | Y | Y | Y | N | *Qualitative *Prospective | All | Medium-high | Medium-high | Medium-high | |
| ERP by fault tree analysis | 1. Context analysis; 2-Risk identification; 3. Risk analysis; 4. Risk evaluation included 4-1. Enterprise resource planning | Weakness: 1-We can only check one event at a specific time | Y | Y | Y | *Qualitative-quantitative | All | Medium-high | Medium-high | Medium-high | ||||
| 2-2: Combined models | ||||||||||||||
| The combined approach(HFMEA, SHERPA) and (STAMP-STPA) | 1. Graphical process included 1-1. Box and arrow diagram; 1–2. HTA Diagram; 1–3. Representation of the control loop; 2. Hazard analysis included 2–1. Failures identification; 2–2. Human error classification; 2–3. Failure scoring; 2–4. Consequence Analysis; 2–5. Check the coherence of severity scores; 2–6. Hazard score calculation; 2–7. Recovery Analysis; 2–8. Selection of the critical failures; 2–9. List of the existing control measures; 3. Cause analysis;4-Identification of prevention measures and controls. | Weakness: The validity and reliability of the combined model have not been measured. | S | Y | Y | Y | S | Y | *Qualitative *Prospective | All, specially for health care | Medium-high | High | High | |
| Problem-solving strategy with embedded Six Sigma methodology | 1. Trained RM team; 2. The define phase; 3. Identify, classify and prioritize risk; 4. RCA; 5-Measures process capability; 6. Prioritize, implement, control and monitor. | Strength: The validity of the model is proven. | Y | S | Y | Y | Y | Y | *Qualitative-quantitative | All | High | High | High | |
| Adaptation of the ISO 31000:2009: Six Sigma DMAIC approach to enterprise RM (ERM) | 1. Define phase(Mandate and commitment); 2. Measure phase included identify risk; 3. Analyze phase included risk analysis; 4. Improve phase including risk mitigation; 5. Control phase including 5-1. The recommended improvement action plan be documented; 5–2. Monitor and review; 6. Communicate and consult. | Strength: | Y | Y | Y | Y | Y | Y | *Qualitative-quantitative | All | High | High | High | |
| Error prevention methods: | 1. | Strength: Is an effective way to prevent errors in organizations. | Y | Y | Y | Y | Y | Y | *Qualitative-quantitative | All, special for health care | High | High | High | |
Notes: In output and information item, the status of risk management in organization was determined based on each of the phases of proposed framework. (Y: Fully performed, S: Somewhat performed, N: Not implemented).